塞来昔布(Celecoxib) - 药物靶点：COX-2_在研适应症：偏头痛，疼痛，牙痛_专利_临床

概要

基本信息

简介CELEBREX是一种非甾体抗炎药。Celecoxib具有镇痛，抗炎和退热作用。CELEBREX的作用机制被认为是通过抑制前列腺素合成，主要通过抑制COX-2而实现的。Celecoxib是体外前列腺素合成的强效抑制剂。治疗期间达到的Celecoxib浓度已经产生了体内效果。前列腺素使传入神经末梢变得敏感，并增强了缓激肽诱导动物模型疼痛的作用。前列腺素是炎症介质。由于Celecoxib是前列腺素合成的抑制剂，因此其作用机制可能是通过减少外周组织中的前列腺素而实现的。CELEBREX适用于骨关节炎（OA），类风湿性关节炎（RA），少年类风湿性关节炎（JRA），强直性脊柱炎（AS），急性疼痛，原发性痛经。它最初由辉瑞公司在1998年在美国上市，用于治疗关节炎。

药物类型

小分子化药

别名

Celecoxib (JAN/USP/INN)、p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide、AD-2111

+ [22]

靶点

COX-2

作用机制

COX-2抑制剂(环氧化酶-2抑制剂)

治疗领域

肿瘤免疫系统疾病感染+ [7]

在研适应症

偏头痛疼痛牙痛+ [18]

非在研适应症

光化性角化病食管腺癌前列腺腺癌+ [47]

原研机构

Pfizer Inc.

在研机构

Astellas Pharma, Inc.Viatris Pharmaceutical GKUpjohn EESV

+ [7]

非在研机构

Pfizer Inc.

Viatris, Inc.Dr. Reddy's Laboratories Ltd. (Russia)

+ [10]

最高研发阶段批准上市

首次获批日期

美国 (1998-12-31),

骨关节炎类风湿关节炎

最高研发阶段(中国)批准上市

特殊审评加速批准 (美国)、孤儿药 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C17H14F3N3O2S

InChIKeyRZEKVGVHFLEQIL-UHFFFAOYSA-N

CAS号169590-42-5

关联

696

项与塞来昔布相关的临床试验

IRCT20200306046708N1

/ Suspended临床2/3期IIT

Celecoxib added to mood stabilizer for treating acute mania: A randomized, double-blind, placebo-controlled trial

开始日期2633-12-15

申办/合作机构

Mashhad University of Medical Sciences

NCT03590821

/ Not yet recruiting早期临床1期IIT

Modulating Celecoxib Induced Blood Pressure Changes by Timed Administration of Aspirin and the Human Chronobiome

To determine whether timed administration of aspirin ameliorates the effects of celecoxib on blood pressure.

开始日期2026-12-01

申办/合作机构

University of Pennsylvania

NCT04860635

/ Suspended临床2/3期

An Open Label Safety Study of a Single Administration of F14 in Patients Undergoing Unilateral Total Knee Replacement

Open-label single-arm study in which all subjects receive F14 as part of a scheduled TKR and multimodal analgesia

开始日期2025-08-01

申办/合作机构

Arthritis Innovation Corp.

100 项与塞来昔布相关的临床结果

登录后查看更多信息

100 项与塞来昔布相关的转化医学

登录后查看更多信息

100 项与塞来昔布相关的专利（医药）

登录后查看更多信息

11,304

项与塞来昔布相关的文献（医药）

2025-04-01·Materials Today Bio

Hydrogel inspired by "adobe" with antibacterial and antioxidant properties for diabetic wound healing

Article

作者: Zhu, Shaobo ; Li, Zouwei ; Li, Jingfeng ; E, Yan ; Chen, Renxin ; Hao, Zhuowen ; Guo, Qi

With the aging population, the incidence of diabetes is increasing. Diabetes often leads to restricted neovascularization, antibiotic-resistant bacterial infections, reduced wound perfusion, and elevated reactive oxygen species, resulting in impaired microenvironments and prolonged wound healing. Hydrogels are important tissue engineering materials for wound healing, known for their high water content and good biocompatibility. However, most hydrogels suffer from poor mechanical properties and difficulty in achieving sustained drug release, hindering their clinical application. Inspired by the incorporation of fibers to enhance the mechanical properties of "adobe," core-shell fibers were introduced into the hydrogel. This not only improves the mechanical strength of the hydrogel but also enables the possibility of sustained drug release. In this study, we first prepared core-shell fibers with PLGA (poly(lactic-co-glycolic acid)) and PCL (polycaprolactone). PLGA was loaded with P2 (Parathyroid hormone-related peptides-2), developed by our group, which promotes angiogenesis and cell proliferation. We then designed a QTG (QCS/TA/Gel, quaternary ammonium chitosan/tannic acid/gelatin) hydrogel, incorporating the core-shell fibers and the anti-inflammatory drug celecoxib into the QTG hydrogel. This hydrogel exhibits excellent antibacterial properties and biocompatibility, along with good mechanical performance. This hydrogel demonstrates excellent water absorption and swelling capabilities. In the early stages of wound healing, the hydrogel can absorb the wound exudate, maintaining the stability of the wound microenvironment. This hydrogel promotes neovascularization and collagen deposition, accelerating the healing of diabetic wounds, with a healing rate exceeding 95 % by day 14. Overall, this study provides a promising strategy for developing tissue engineering scaffolds for diabetic wound healing.

2025-03-04·Journal of biomolecular structure & dynamics

Design and construction of novel pyridine-pyrimidine hybrids as selective COX-2 suppressors: anti-inflammatory potential, ulcerogenic profile, molecular modeling and ADME/Tox studies

Article

作者: Bakr, Rania B. ; Ghoneim, Mohammed M. ; Alsalahat, Izzeddin ; Alotaibi, Nasser Hadal ; Hazem, Sara H. ; Shaker, Mohamed E. ; Azouz, Amany A. ; Farouk, Amr ; El-Mesery, Mohamed E. ; Musa, Arafa ; Abdelgawad, Mohamed A. ; Goma, Hesham A. M. ; Abdel-Bakky, Mohamed Sadek ; Alzarea, Sami I. ; Elkanzi, Nadia A. A. ; Alsahli, Tariq G.

NSAIDs represent a mainstay in pain and inflammation suppression, and their actions are mainly based on inhibiting COX-1 and COX-2 enzymes.Due to the adverse effects of these drugs, especially on the stomach and heart, scientists efforts have been directed to manufacture selective COX-2 without cardiovascular side effects and with minimal effects on the stomach. The cardiovascular side effects are thought to be related to the chemical composition rather than mechanism of action of these drugs.Novel pyridopyrimidines, 9a-j, were prepared and their chemical structures were confirmed by NMR, mass and IR Spectra, and elemental analysis. The effect of the 9a-j compounds on COX-1 and COX-2 was assessed and it was found that 2-hydrazino-5-(4-methoxyphenyl)-7-phenyl-3H-pyrido[2,3-d)pyrimidin-4-one (9d) was the most potent COX-2 inhibitor (IC₅₀ = 0.54 uM) compared to celecoxib (IC₅₀ = 1.11 uM) with selectivity indices of 6.56 and 5.12, respectively.The in vivo inhibition of paw edema of novel compounds 9a-j was measured using carrageenan-induced paw edema method, and that 2-hydrazino-5-(4-methoxyphenyl)-7-phenyl-3H-pyrido[2,3-d)pyrimidin-4-one (9d) showed the best inhibitory activity in comparison with the other compounds and celecoxib.The gastroprotective effect of the potent derivatives 9d, 9e, 9f, 9 g and 9h was investigated. 2-Hydrazino-5-(4-methoxyphenyl)-7-phenyl-3H-pyrido[2,3-d)pyrimidin-4-one (9d) and 7-(chlorophenyl)-hydrazino-5-(4-methoxyphenyl)-3H-pyrido[2,3-d)pyrimidin-4-one (9e) showed ulcer indices comparable to celecoxib (1 and 0.5 vs 0.5, respectively). Docking studies were carried out and they confirmed the mechanistic action of the designed compoundsCommunicated by Ramaswamy H. Sarma.

2025-03-01·BIOORGANIC CHEMISTRY

Exploration of anti-inflammatory activity of pyrazolo[3,4-d]pyrimidine/1,2,4-oxadiazole hybrids as COX-2, 5-LOX and NO release inhibitors: Design, synthesis, in silico and in vivo studies

Article

作者: Ibrahim, Tarek S ; Salem, Ibrahim M ; Al-Awadh, Mohammed A ; Allam, Rasha M ; Aziz, Marwa A ; Alharbi, Abdulrahman S ; Ahmed, Osama A A ; Elsayed Abouzed, Deiaa E ; Abuo-Rahma, Gamal El-Din A ; Mohamed, Mamdouh F A

New pyrazolo[3,4-d]pyrimidine derivatives 7a-h and 8a-h were synthesized and evaluated for their in vitro inhibitory potential against COX-1, COX-2, 5-LOX along with the NO release inhibitory activity to assess their anti-inflammatory potential. Most compounds confered inhibitory activity at a micromolar level and exhibited prominent selectivity towards COX-2 especially in the 8a-h series. The most useful compound 8e as a COX-2/5-LOX dual inhibitor, exhibited IC₅₀ results of; 1.837 µM for COX-2, 2.662 µM for 5-LOX with an acceptable NO release inhibition rate of 66.02 %. Compounds 7e, 7f, 8e and 8f proved their efficiency as 5-LOX/NO release dual inhibitors; with IC₅₀ values of 2.833, 1.952, 2.662 and 1.573 µM, respectively for 5-LOX biotarget, and with superior NO inhibitory ratio of 73.85, 65.57, 66.02 and 72.28 %, respectively. The in vivo anti-inflammatory assay explored that 7e is the most effective with minimal gastric ulceration prevalence. Molecular docking in the active site of both COX-2 and 5-LOX showed that, the most active 8e and 7e are correctly oriented inside the COX-2 binding pocket with unique binding mode independently on the reference celecoxib. Also, they demonstrated superior binding affinities to the 5-LOX enzyme over both the Zileuton as a reference drug and the normal ligand 30Z. The stability of the complex formed between the most promising candidates 7e or 8e with the COX-2 and 5-LOX active sites, was considered using a typical atomistic 100 ns dynamic simulation study. Investigation of the SAR revealed the importance of both the sulfonamide group in the 8a-h series and the substituents of the 3-phenyl ring tethered on the 1,2,4-oxadiazole core.

401

项与塞来昔布相关的新闻（医药）

2025-02-06

·CPHI制药在线

黑热病治疗新靶点展望

关注并星标CPHI制药在线利什曼病，又被称为黑热病，是人体被利什曼原虫感染所致的播散性原虫病。有20个种类的利什曼原虫可引起利什曼病，大约30种不同的白蛉亚科沙蝇可以通过叮咬传播利什曼原虫，利什曼原虫感染已经成为许多热带和亚热带国家人群重要的卫生健康问题，是仅次于疟疾的最危险的且被忽视的热带病，每年可造成50,000例死亡和330万伤残。利什曼病疫苗接种是一种有吸引力且可行的替代方法，但迄今还没有疫苗或药物能完全根除或提供对利什曼病长期有效的免疫力。它有多种临床表现形式，如内脏利什曼病、皮肤利什曼病、粘膜利什曼病。世界卫生组织估计，该疾病每年影响 103 万人。目前临床治疗黑热病可供选择的药物种类少，治疗方法包括抗睾丸素、两性霉素 B 和米替福新，都受到了副作用、成本、耐药性和减毒等因素的制约。探索新的治疗靶点，如关键的代谢酶和表面活性蛋白，可能会开发出更有效和无毒的药物。治疗新靶点展望 1. 钙离子稳态调节剂钙是寄生虫生存所必需的，因此是治疗黑热病的一个靶点。钙离子在利什曼病菌的入侵和新陈代谢中起着至关重要的作用，钙离子浓度可以影响细胞内的信号通路。钙离子浓度的变化会触发寄生虫分化和细胞改变的信号通路。钙离子在调节寄生虫生命周期中的重要作用凸显了靶向钙转运体的潜在治疗作用。最近的研究表明，姜黄素等制剂能通过破坏钙离子转运体，诱导利什曼原虫的程序性细胞死亡。以前报道的钙通道阻滞剂，如芬地林、米贝地尔和利多法嗪等钙通道阻滞剂与常规化疗药物联合使用，具有很强的抗黑热病作用。 2. 铁离子稳态调节剂铁是参与新陈代谢的重要金属离子，通常以亚铁和铁两种状态存在。持续的氧化还原循环使生物体能够进行生存所需的各种重要生物过程。利什曼缺乏铁储存系统，是血红素辅助营养体，因此，铁清除对其生存和毒性至关重要。在缺铁条件下，会表达一种名为利什曼病菌铁转运体的铁转运体，通过提高铁的转运能力来获得所需的铁。铁是线粒体超氧化物歧化酶的关键成分，对氧化还原反应起关键作用，这种化合物可被视为药物开发的潜在目标。 3. 基因组靶点利什曼原虫的基因组结构与其他真核生物相比是独特的，没有内含子，并且由染色体中高度浓缩的基因密度组成在较小的核空间内。这些基因组负责编码各种蛋白质，这些蛋白质参与细胞的功能。其中一组蛋白质是利什曼原虫激酶，参与信号级联的调控，因此有可能成为有希望的分子靶标。最近研究人员开始研究蛋白激酶，如细胞周期蛋白依赖性激酶、糖原合酶激酶 3、双特异性酪氨酸调节激酶和丝裂原活化蛋白激酶等。 4. 蛋白酶体靶点蛋白酶体是一种复杂的蛋白质结构，负责调节蛋白质合成并分解折叠错误的蛋白质，而在原核生物中，被降解的蛋白质会被泛素标记。已经筛选了几种蛋白酶体抑制剂，其中一种是 GSK3494245/ DDD01305143/化合物，并在 2024 年完成了 I 期人体临床试验（https:// clinicaltrials.gov/study/NCT04504435）。此外，GNF6702 是一种细胞蛋白酶抑制剂化合物，诺华公司于 2020 年对其进行了化学优化，目前正在进行第二阶段人体临床试验。 5. 植物提取物从枸橼酸香蒲叶子中提取的精油，从柠檬香蒲叶中提取的精油在体外具有抗利什曼病的作用。此外，芦荟叶提取物通过诱导程序性细胞死亡发挥潜在抗利什曼病特性。 6. 宿主抗原疗法目前利什曼原虫感染的药物治疗效有限，需要长期用药，而且可能会导致严重的全身副作用，其严重程度超过了治疗效果。因此，要成功治疗由细胞内病原体引起的疾病，可能需要使用综合疗法和高效的给药方法。目前，咪喹莫特和雷喹莫特被用于治疗利什曼病AR-12 是塞来昔布的一种衍生物，可以增强宿主细胞对凋亡的抵抗力，可能破坏寄生虫诱导的 Akt 信号激活。辛伐他汀、洛伐他汀被用作局部或全身的宿主导向药物疗法，可抑制胆固醇的生成，促进巨噬细胞中吞噬体的成熟，从而提高寄生虫的清除率。 7. 纳米药物寄生虫的复杂生命周期和细胞内定位导致生物利用率较低，疗效降低。生物传感器和纳米载体辅助治疗和免疫，可彻底改变利什曼病的诊断、管理和预防。以纳米粒子为基础的递送系统通过改善靶向递送和抗原，纳米颗粒给药系统通过改善靶向给药和抗原呈递，刺激免疫系统，促进强大的 T 细胞反应，并在传染病防治中提供保障。脂质体纳米颗粒是一种水性支架，有助于亲水性和亲油性药物的附着，在体内的持久性更强，可在血液中停留较长时间，脂质体能以较低的剂量和给药频率持续、规范地释放药物。不同的纳米材料，如固体脂质纳米粒子、纳米悬浮剂、聚合物基纳米粒子、聚乙烯醇等不同的纳米材料，可以作为治疗利什曼病的各种药物的载体材料。参考文献 1. Singh VK, Tiwari R, Rajneesh, et al. Advancing Treatment for Leishmaniasis: From Overcoming Challenges to Embracing Therapeutic Innovations. ACS Infect Dis. 2024 Dec 31. 2. Kumar, R.; Chauhan, S. B.; Ng, S. S.; et al. Immune checkpoint targets for host-directed therapy to prevent and treat leishmaniasis. Front Immunol. 2017, 8, 1492. 3. Jamshaid, H.; Din, F. U.; Khan, G. M. Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight. J. Nanobiotechnology. 2021, 19, 1?51. 扫码领取CPHI & PMEC China 2025展会门票【智药研习社近期直播】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

疫苗

2025-01-28

·汇聚南药

除了头孢，服这7类药物饮酒也致命！

都说“酒后不吃药，吃药不喝酒”，但经常有人不当回事。上个月一同事感冒吃药后参加了一个饭局，喝了点酒，结果当晚半夜就感到身体极度不适，胸闷气短。被120送到医院抢救了一个晚上，终于从死神怀里把他拉了回来。说起此事，这个同事便后怕不已，自此以后彻底戒酒了。严格意义上讲，只要是吃了药，就不再适宜饮酒了。不管是红酒啤酒还是白酒，只要吃了药，在停药后至少1~3天内也是不适宜喝酒的。其中有几大类药物对酒精的反应特别致命的，服用了这几类药物再饮酒的话，就会引发一系列医学上称为双硫仑反应的极度不适，进而危及生命。什么是双硫仑反应吃药后喝酒引起的反应称之为双硫仑反应。双硫仑本身是一种戒酒药物，双硫仑在与乙醇联用时可抑制肝脏中的乙醛脱氢酶，使乙醇在体内氧化为乙醛后，不能再继续分解氧化，导致体内乙醛蓄积而产生一系列反应。许多药物具有与双硫仑相似的作用，用药后若饮酒，会发生面部潮红、眼结膜充血、视觉模糊、头颈部血管剧烈搏动或搏动性头痛、头晕、恶心、呕吐、出汗、口干、胸痛、心肌梗塞、急性心衰、呼吸困难、急性肝损伤、惊厥及死亡等。第一类：头孢菌素类抗生素(包括头孢哌酮、头孢哌酮舒巴坦、头孢曲松、头孢唑林(先锋ⅴ号)、头孢拉啶(先锋ⅵ号)、头孢美唑、头孢米诺、拉氧头孢、头孢甲肟、头孢孟多、头孢氨苄(先锋ⅳ号)、头孢克洛等)、痢特灵、氯霉素、呋喃妥因、甲硝唑等头孢类+酒=毒药在吃过头孢类的药物，或是打了头孢类的消炎针之后，再喝酒，就会出现“双硫仑样反应”！那么它到底是什么？它又称为戒酒硫样反应，主要是因为口服头孢类药物后食用酒精，导致体内乙醛积蓄产生的中毒反应。主要表现为胸闷、气短、喉头水肿、口唇紫绀、呼吸困难、心率增快、血压下降、幻觉、恍惚、甚至发生过敏性休克。另外，双硫仑样反应严重程度与应用药物的剂量、饮酒量呈正比。饮用白酒较啤酒、含酒精饮料等反应重，用药期间饮酒较停药后饮酒反应重。本身就有心血管基础病的人，有可能严重到造成呼吸抑制、心力衰竭乃至死亡。那么，饮酒和吃药，到底间隔多久才是安全的呢？一项调查分析显示：饮酒后5天之内的人，吃头孢类抗生素都可能发生双硫仑样反应。喝酒6天以后，再服药，是安全的。第二类：镇静催眠类药物安眠药+酒=一条人命如苯巴比妥、水合氯醛、安定、利眠宁这些大脑抑制剂，在乙醇的作用下，会被人体加速吸收，同时还会减慢其代谢速度，使药物成分在血液中的浓度在短期内迅速增高。饮酒后，酒精对大脑中枢神经系统先兴奋后抑制，加上这些大脑抑制剂，使中枢神经系统正常活动受到严重抑制，可使患者出现昏迷、休克、呼吸衰竭、死亡等。据说，喜剧大师卓别林就死于酒后服用安眠药。安眠药（艾司唑仑或唑吡坦）如果与酒精合用会造成危险后果，因为酒精会加重安眠药的镇静效果，对大脑活动有抑制作用，会引起严重的困倦和眩晕。如果服用者在活动状态下，还会增加跌倒、受伤和出车祸的风险。服用安眠药的同时大量饮酒会让血压降低到极低的水平，并导致呼吸困难。第三类：解热镇痛剂类止痛药+酒=消化道出血如阿司匹林、扑热息痛等。这类药本身对胃黏膜有刺激和损伤作用，而酒精也伤胃，两者双管齐下，可导致胃炎、胃溃疡、胃出血等。第四类：利血平、抗癌剂、“异烟肼”(抗结核药)等药物降压药+酒=低血压休克酒有很多种，如果服此类药后喝的是葡萄酒，则容易出事。服用降压药的朋友，包括利血平、卡托普利、硝苯地平这些降压药，如果饮酒，可能引起血管舒张，出现低血压，甚至休克、危及生命。皆因葡萄酒含有的酪胺，若大量积蓄，会对人体造成重大伤害，导致头晕头痛、恶心呕吐、腹泻、心律失常、血压升高甚至脑溢血。正常饮用时，其中的酪胺可被人体自然破坏，但若服下此类药后，人体却无法成功破坏酪胺，难免就容易出事了，后果还相当严重。第五类：降糖药降糖药+酒=低血糖休克糖尿病人也要格外注意了，注射胰岛素或口服降糖药期间，空腹饮酒的话，容易出现低血糖反应。酒精会刺激胰岛素分泌，而如果患者刚服完降糖药，血糖已降到标准值，这时酒精使胰岛素增加分泌，势必会引起低血糖。尤其在服用格列苯脲或注射胰岛素后饮酒，出现低血糖的几率更高。另外，像二甲双胍这类降糖药，如果与酒精混用可能会出现一种罕见但非常严重的副作用——它会增加乳酸性酸中毒的风险，即乳酸在血液中堆积起来，导致恶心、无力等症状。再者，长期喝酒在引起肝损害的同时，还会增加酮症发生的概率。因为酒精会对抗身体的胰岛素，抑制肝脏的糖代谢。所以如果糖尿病患者大量饮酒，有可能会诱发酮症。值得警惕的是，这种低血糖症状表现为心慌、出汗、疲乏无力，甚至烦躁、意识混乱、多语。这些症状常常被醉酒反应掩盖，不易与醉酒区别。这导致了即使出现严重而持久的低血糖，患者往往浑然不觉，最终发生低血糖性休克。如果不及时治疗，可能会导致脑组织不可逆的损害，甚至引起死亡。第六类：抗抑郁药抗抑郁药+酒=加重病情、血压上升抗抑郁药和饮酒都会延缓中枢神经系统的运行节奏，影响到大脑的功能和思维能力，削弱警觉性。两者结合在一起会让人感到困倦，降低人们的判断能力、身体协调能力和反应时间，甚至还会导致抑郁症的症状恶化。对于服用单胺氧化酶抑制剂的抑郁症患者来说，酒精还会与这类药物发生交互作用，使得血压上升，有一定危险性，因此医生会建议这类患者完全避免饮酒。而对于服用选择性5-羟色胺再摄取抑制剂（比如舍曲林、盐酸氟西汀和帕罗西汀）的抑郁症患者来说，虽然还没有充足证据证明药品会与酒精发生不利反应，但由于酒精会使患者头晕、嗜睡和注意力不集中，因此还是建议最好不要饮酒。第七类：治疗关节炎类药物治疗关节炎类药物+酒=胃溃疡、肝损伤如塞来昔布、萘普生、双氯芬酸钠等。上述药物与酒精混合服用时会引起溃疡、胃出血、肝损伤等副作用。服用塞来昔布，就不能喝酒，特别是药物已经引起更高的心血管副作用的风险，如心脏病发作和中风，而酒精会增加这种风险。做到这些事，小酌更放心除了用药禁忌外，喝酒的一些小细节，也可能会影响健康。喝酒前，吃点东西，别空腹在喝酒之前，可先食用一些高脂肪、高蛋白或“高碳水”类食物（如酸奶、馒头、面包、面条或米饭等），既能避免醉得太快，也能减少酒精对食管、胃产生的直接刺激与损伤。 “空腹喝酒时，血液吸收酒精的速度会变快，血液中的酒精浓度更容易达到一定值，所以更容易喝醉。”北京佑安医院肝病中心主任医师赵国庆表示。不要混着喝白酒、啤酒、红酒不要混着喝。各种酒混在一起喝，首先就会让我们不自觉地饮酒过量。而且两种以上的酒混着喝还会表现出某种“协同作用”，对人体伤害更大。注意喝酒量《中国居民膳食指南（2022）》提醒，如果喝酒，成年人一天最大饮酒的酒精量建议不超过15克。 △图源：《中国居民膳食指南》别喝得太快广州医科大学附属第五医院泌尿外科二区主任李天表示，饮酒后乙醇在几分钟内就可进入血液，30—120分钟血中的乙醇浓度就可达到最高。喝得快会让乙醇浓度升高得快，很快就会进入醉酒状态。别与碳酸饮料混喝一些人认为酒中加入碳酸饮料可以稀释酒精浓度，也能让口感变好，导致越喝越多。李天提醒，碳酸饮料里面的二氧化碳，不仅会撑大胃的容积，还会加快酒精从胃进入小肠的速度，而小肠比胃对酒精的吸收能力要强得多。喝酒间隙多喝水李天建议，饮酒时多喝水，有利于促进酒精的稀释和代谢，加速酒精排泄出体外的进程，也可减少酒后口渴等不适。 03 如何缓解宿醉带来的不适？宿醉带来的不适可以借助以下方法来缓解：补水宿醉主要是由身体脱水引起的。饮酒过量会对胃黏膜产生刺激，导致恶心、呕吐，再加上酒精利尿，诸多因素叠加会导致身体严重缺水，故宿醉特别是呕吐后要及时补水。如果是空腹饮酒，还要注意保暖和补充糖类，可以喝一些椰子汁。不建议用浓茶或咖啡来解酒茶有利尿作用，而人在过量饮酒后，酒精里的乙酸还没有完全排出去，这个时候喝茶，尤其是浓茶，容易对肾脏造成伤害。而咖啡会让人的大脑兴奋，身体里的血液流动也随之加速，虽然这样可以加快酒精的代谢，但会给心脏和血管带来很大负担。如果是患有心脑血管疾病的老年人，会因为酒精和咖啡的双重作用导致血压升高，造成风险。身体不适时注意平躺休息饮酒后如果感觉头痛欲裂或头晕，建议平躺休息，以免身体因为不能维持平衡而摔倒。食用有解酒功效的食物可以吃生姜、番茄、芦笋、柿子、香蕉和蜂蜜等食物来缓解宿醉的不适。宿醉者醒来后可以吃些香蕉、芦笋、小番茄等，这些食材可补充维生素；还可以再食用一杯牛奶冲泡的麦片，以补充碳水和蛋白质。除了宿醉带来的身体不适，饮酒的危害还远不止于此。许多研究证实酒精是导致疾病的重要因素。想要避免酒精对身体的伤害，最好的办法还是远离酒精。生活是美好的，我们在享受生活的同时，千万不要拿自己的生命和健康开玩笑，不要和自己下这样的生命赌注。喜欢我们文章的朋友点个“在看”和“赞”吧，不然微信推送规则改变，有可能每天都会错过我们哦~ 免责声明 “汇聚南药”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请在留言栏及时告知，我们会在24小时内删除相关信息。信息来源：连锁药店药评中心往期推荐本平台不对转载文章的观点负责，文章所包含内容的准确性、可靠性或完整性提供任何明示暗示的保证。

AHA会议

2025-01-25

·Business Wire

Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer

AUSTIN, Texas,--( BUSINESS WIRE )-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB (Alliance) / SWOG 80702 study. The study will be presented today, Jan. 25, 2025 as a late-breaking oral presentation at the 2025 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, CA. This first-of-its-kind study evaluated whether Signatera-positive patients benefit from an escalation in adjuvant treatment. In the trial, Signatera was used to evaluate the benefit of adding celecoxib, a non-steroidal anti-inflammatory drug (NSAID), to standard of care (SOC) adjuvant chemotherapy with FOLFOX in the management of stage III colorectal cancer (CRC). The pre-specified analysis included approximately 1,000 patients with available post-surgical plasma samples, who were randomized to receive FOLFOX (+/-) celecoxib. Key findings included: Signatera-positivity after surgery was predictive of a disease-free survival (DFS) and overall survival (OS) benefit with the addition of celecoxib to adjuvant FOLFOX. The addition of celecoxib to SOC chemotherapy significantly improved DFS compared to placebo (HR 0.55, 95% CI 0.39-0.80; p=0.001) among Signatera-positive patients with a three-year DFS of 44.1% versus 26.6%. Similar results were seen for OS (HR 0.58, 95% CI 0.38-0.90; p=0.013). No survival benefit was seen by adding celecoxib to chemotherapy in Signatera-negative patients. Signatera status after surgery and prior to starting adjuvant therapy was highly predictive of recurrence. Signatera-positivity was significantly associated with worse DFS (HR 7.14, 95% CI: 5.54-9.21; p<0.0001) and OS (HR 6.72, 95% CI: 4.91-9.18; p<0.0001). “ The results from the CALGB (Alliance) / SWOG 80702 study mark an unprecedented moment in personalized medicine for patients with colorectal cancer,” said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology for Natera. “ We demonstrated Signatera’s ability to predict a benefit in both disease-free survival and overall survival for Signatera-positive patients from the addition of celecoxib, an extremely accessible, affordable, and well-tolerated therapy. These data also offer compelling evidence to address an unmet need in adjuvant colorectal cancer treatment, where there has not been a new drug approval in over 20 years.” The results of the randomized, double-blind ALTAIR clinical trial will also be presented in a poster today. ALTAIR examined treatment escalation with Trifluridine/Tipiracil (FTD/TPI) in patients with stage I-IV colorectal cancer. In the trial, 243 Signatera-positive patients were randomized to FTD/TPI or placebo over a six-month treatment period. The results showed a trend toward benefit in the FTD/TPI group (median DFS of 9.3 months vs. 5.6 months in the placebo group), although it did not reach statistical significance (HR, 0.79; P = 0.107). There was a significant benefit for resected oligometastatic stage IV patients treated with FTD/TPI, showing a median DFS of 9.76 months as compared to 3.96 months in the placebo group (HR, 0.53; P = 0.012). This presents an opportunity for clinical benefit in stage IV patients who test positive for MRD. About Signatera Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard-of-care tools, and help optimize treatment decisions. The test is available for clinical and research use and is covered by Medicare for patients with colorectal cancer, breast cancer, ovarian cancer, and muscle-invasive bladder cancer, as well as for immunotherapy monitoring of any solid tumor. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in over 100 peer-reviewed papers. About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com . Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov .

临床结果临床3期ASCO会议免疫疗法

100 项与塞来昔布相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00567	塞来昔布	L01XX33 M01AH01	DB00482

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
偏头痛	美国	Scilex Pharmaceuticals, Inc.	2020-05-05
疼痛	日本	Astellas Pharma, Inc.	2011-12-22
牙痛	日本	Viatris Pharmaceutical GK	2011-12-22
滑囊炎	日本	Viatris Pharmaceutical GK	2009-06-17
颈臂综合征	日本	Viatris Pharmaceutical GK	2009-06-17
颈臂综合征	日本	Astellas Pharma, Inc.	2009-06-17
腰痛	日本	Viatris Pharmaceutical GK	2009-06-17
腰痛	日本	Astellas Pharma, Inc.	2009-06-17
关节周围炎	日本	Astellas Pharma, Inc.	2009-06-17
肌腱病	日本	Astellas Pharma, Inc.	2009-06-17
肌腱病	日本	Viatris Pharmaceutical GK	2009-06-17
腱鞘炎	日本	Viatris Pharmaceutical GK	2009-06-17
镇痛	日本	Viatris Pharmaceutical GK	2007-01-26
炎症	日本	Viatris Pharmaceutical GK	2007-01-26
幼年特发性关节炎	美国	Upjohn US 2 LLC	2006-12-15
原发性痛经	美国	Upjohn US 2 LLC	2001-10-18
急性疼痛	中国	Viatris Pharmaceuticals LLC	2000-08-01
强直性脊柱炎	瑞典	Upjohn EESV	2000-03-29
腺瘤性结肠息肉病	美国	Viatris Holdings LLC	1999-12-23
骨关节炎	美国	Upjohn US 2 LLC	1998-12-31

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
先兆偏头痛	申请上市	加拿大	Scilex Holding Co.	2023-12-26
无先兆偏头痛	申请上市	加拿大	Scilex Holding Co.	2023-12-26
光化性角化病	临床3期	美国	Dr. Reddy's Laboratories Ltd. (Russia)	2017-02-14
痛风性关节炎	临床3期	美国	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	加拿大	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	哥伦比亚	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	哥斯达黎加	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	墨西哥	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	秘鲁	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	菲律宾	Viatris, Inc.	2008-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03643744 (CTgov)	临床1期	光化性角化病	12	Celecoxib 200mg (PDT + Celecoxib)	鹹獵鹽齋遞鹽蓋鹹蓋衊(窪網簾齋構醖蓋遞醖鏇) = 夢醖積餘築繭鑰蓋夢簾壓獵鹽獵淵餘夢鹽網積 (選鏇積製壓鹹鬱夢簾糧, 廠願構鹽築願築憲製繭 ~ 襯鏇憲夢遞淵顧繭壓淵) 更多	-	2024-12-19
				Placebo (PDT + Placebo)	鹹獵鹽齋遞鹽蓋鹹蓋衊(窪網簾齋構醖蓋遞醖鏇) = 衊獵獵襯蓋築鹹築糧鏇壓獵鹽獵淵餘夢鹽網積 (選鏇積製壓鹹鬱夢簾糧, 壓壓廠構蓋衊淵餘廠蓋 ~ 夢夢艱鹽廠壓襯鹽範網) 更多
NCT04765644 (ASCENT, CTgov)	临床4期	-	44	Celecoxib+L-arginine (Celecoxib)	遞獵夢鬱鏇繭壓膚遞蓋(蓋鬱顧鬱繭糧齋築廠憲) = 顧築繭鑰鹹構艱獵顧衊築鬱範網構範壓襯淵壓 (夢選壓範艱網顧選膚襯, 選夢鏇顧簾遞糧壓繭壓 ~ 齋願獵選醖遞餘糧衊築) 更多	-	2024-10-28
				Placebo+L-arginine + placebo (Placebo)	遞獵夢鬱鏇繭壓膚遞蓋(蓋鬱顧鬱繭糧齋築廠憲) = 鹹選淵糧鬱蓋鑰鹽鑰艱築鬱範網構範壓襯淵壓 (夢選壓範艱網顧選膚襯, 範廠艱蓋壓鬱積淵膚醖 ~ 蓋淵構蓋構顧鹽餘築範) 更多
NCT03859024 (CTgov)	临床4期	尿道狭窄 \| 术后疼痛	48	Acetaminophen+Ibuprofen 800 mg+Oxycodone (Standard Protocol)	積獵積糧醖繭壓蓋鹽觸(糧鏇範製遞醖廠獵積顧) = 艱窪糧遞觸製襯願夢築構壓餘製餘選鑰憲選繭 (餘顧廠窪鑰醖顧壓衊淵, 糧構糧齋積簾積鹽糧衊 ~ 築網網醖夢顧築餘鏇衊) 更多	-	2024-09-19
				Acetaminophen+Ibuprofen 800 mg+celebrex+Dexamethasone+Oxycodone+Bupivacaine+Gabapentin (Enhanced Recovery Protocol)	積獵積糧醖繭壓蓋鹽觸(糧鏇範製遞醖廠獵積顧) = 憲餘範鑰壓餘鑰鹽艱憲構壓餘製餘選鑰憲選繭 (餘顧廠窪鑰醖顧壓衊淵, 積糧顧顧窪壓獵糧衊繭 ~ 鹹簾淵構艱築鏇選範獵) 更多
NCT05077969 (CTgov)	临床2期	SARS-CoV-2 急性呼吸道疾病	4	Famotidine+Celecoxib (Group 1 (Study Product))	選製糧鹹簾齋積鬱鏇襯(選選齋憲憲構積顧製遞) = 壓廠網積製獵淵遞鑰蓋廠壓淵築簾夢廠窪鑰製 (窪衊構獵糧鹽遞積淵遞, 蓋蓋繭鏇衊選遞糧廠積 ~ 壓願糧製遞衊鬱鏇簾築) 更多	-	2024-07-09
				Placebo (Group 2 (Reference Therapy))	選製糧鹹簾齋積鬱鏇襯(選選齋憲憲構積顧製遞) = 鏇艱構糧鹽鹽窪餘築廠廠壓淵築簾夢廠窪鑰製 (窪衊構獵糧鹽遞積淵遞, 鹹憲膚築獵鏇觸積範糧 ~ 積窪網築範壓鹽製繭壓) 更多
NCT04015908 (CTgov)	临床4期	-	100	Pregabalin+Acetaminophen+Celecoxib+Oxycodone (Multi-modal)	壓餘壓憲淵獵鹽觸積夢(獵餘範醖鬱廠糧糧齋壓) = 築夢艱醖觸網膚淵夢獵繭襯顧窪網廠觸壓糧簾 (願積鹽淵鏇遞艱鏇鬱廠, 憲簾簾膚繭壓簾遞淵範 ~ 窪網鏇衊餘鏇齋艱構鏇) 更多	-	2024-07-08
				Percocet (Control)	壓餘壓憲淵獵鹽觸積夢(獵餘範醖鬱廠糧糧齋壓) = 夢憲鏇鹽製選餘願遞築繭襯顧窪網廠觸壓糧簾 (願積鹽淵鏇遞艱鏇鬱廠, 簾夢鹹壓鹹簾獵範築範 ~ 簾遞齋繭獵鑰鑰淵遞夢) 更多
NCT03006276 \| NCT03009019 (GlobeNewswire) 人工标引	临床3期	偏头痛	-	ELYXYB (Triptan Insufficient Responders)	製願網構夢顧鏇構觸繭(簾餘網簾遞願廠願網積) = 網壓艱觸夢鹽鹹鹹憲繭蓋鹽鹽艱築築衊構鏇艱 (襯壓艱觸鹹積蓋鬱衊壓 )	积极	2024-06-13
				placebo (Triptan Insufficient Responders)	製願網構夢顧鏇構觸繭(簾餘網簾遞願廠願網積) = 範鬱憲簾繭鬱範鹹簾範蓋鹽鹽艱築築衊構鏇艱 (襯壓艱觸鹹積蓋鬱衊壓 )
NCT01479829 (CTgov)	临床4期	抑郁症 \| 炎症	100	Escitalopram+Celecoxib (Intervention Cohort)	網廠膚顧蓋糧繭鬱選鬱(觸鬱膚壓憲繭壓衊顧糧): Chi-square value = 5.3466, P-Value = 0.02 更多	-	2024-04-09
				Placebo+Escitalopram (Control Cohort)
NCT03818919 (CTgov)	临床2期	镇痛 \| 肩袖撕裂关节病	70	Acetaminophen+Diazepam+Ketorolac+Celecoxib+Gabapentin (Post-Operative Non Opioid Pain Protocol)	鏇網顧窪夢願壓鹹淵膚(壓齋選築選築製鹹網鏇) = 觸鹽簾製遞築簾顧襯顧選糧獵蓋醖遞鹹遞築構 (網糧鑰憲簾襯遞蓋範製, 選壓鹹夢夢餘獵齋廠顧 ~ 餘襯憲憲壓觸餘鏇觸淵) 更多	-	2024-04-02
				Hydrocodone-Acetaminophen (Post-Operative Traditional Pain Protocol)	鏇網顧窪夢願壓鹹淵膚(壓齋選築選築製鹹網鏇) = 積獵顧蓋製鏇膚膚製糧選糧獵蓋醖遞鹹遞築構 (網糧鑰憲簾襯遞蓋範製, 壓築醖積壓醖構壓蓋顧 ~ 醖鏇鬱鹽製顧築顧鏇顧) 更多
NCT04790812 (CTgov)	临床4期	牙痛 \| 术后疼痛	65	Placebo+Celecoxib (Celecoxib Plus Placebo)	鹹網衊顧鬱窪遞顧積製(遞襯製齋襯築糧獵鑰齋) = 遞製蓋醖顧獵鹽範構範鹹蓋鑰窪觸網蓋夢製鑰 (膚糧獵鬱壓餘鹹構糧鹽, 壓蓋艱鑰襯範壓鏇觸壓 ~ 鏇鑰製憲獵鏇壓獵衊膚) 更多	-	2024-03-27
				Acetaminophen+Celecoxib (Celecoxib Plus Acetaminophen)	鹹網衊顧鬱窪遞顧積製(遞襯製齋襯築糧獵鑰齋) = 鬱鹽壓衊壓積顧鹹鏇糧鹹蓋鑰窪觸網蓋夢製鑰 (膚糧獵鬱壓餘鹹構糧鹽, 鹽構夢醖淵築膚淵網齋 ~ 夢艱鑰願獵繭齋膚衊鹹) 更多
NCT02502006 (CTgov)	临床1期	-	16	Celecoxib (Celecoxib)	獵獵選醖鏇齋鏇簾膚鹹(願積壓鬱壓鑰廠齋顧遞) = 簾網積廠廠築壓構簾夢願憲齋窪積範網鹹襯獵 (廠顧觸觸繭築廠繭鹹鬱, 獵齋窪鹽顧淵築壓餘願 ~ 構顧製壓範餘糧淵簾壓) 更多	-	2023-12-13
				Naproxen (Naproxen)	獵獵選醖鏇齋鏇簾膚鹹(願積壓鬱壓鑰廠齋顧遞) = 衊廠醖夢艱壓構鏇憲鬱願憲齋窪積範網鹹襯獵 (廠顧觸觸繭築廠繭鹹鬱, 餘窪製構醖願蓋獵積壓 ~ 膚遞艱糧餘憲網積構廠) 更多